Anika Therapeutics (NasdaqGS:ANIK) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Anika Therapeutics to reach your target.
Hmm, we can't give any reliable projection for Anika Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| ANIK Price (Anika Therapeutics stock price per share) |
$13.62 | |
| PE Ratio versus Sector | 122% higher than other Unknown stocks | |
| PE Ratio versus Industry | 22% lower than other Unknown stocks | |
| Cash Yield | 22.72% | |
| Free Cash Flow Jitter | 100% |
In the six months to 2026-11-18, 1 insider bought in 2 trades, about $41 thousand, and no insider sold shares.
The six months before that had 2 buys and 0 sales.
Open-market buys and sells reported by Anika Therapeutics's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-04 | Fischetti Gary P | Buy | 1,000 | $20.32 |
| 2026-08-03 | Fischetti Gary P | Buy | 1,000 | $20.75 |
| 2026-05-01 | HENNEMAN JOHN B III | Buy | 5,000 | $14.66 |
| 2026-04-30 | Griffin Stephen D. (President and CEO) | Buy | 12,200 | $12.29 |
| 2022-05-11 | Colleran David (EVP, General Counsel, Corp Sec) | Buy | 1,500 | $21.37 |
| 2022-03-14 | Colleran David (EVP, General Counsel, Corp Sec) | Buy | 1,500 | $26.65 |
| 2022-03-11 | Levitz Michael L (EVP, CFO, Treasurer) | Buy | 4,000 | $24.62 |
| 2022-03-11 | Blanchard Cheryl R (President, CEO, Director) | Buy | 3,813 | $25.81 |
| 2022-03-11 | Blanchard Cheryl R (President, CEO, Director) | Buy | 4,287 | $25.36 |
| 2022-03-11 | Thompson Jeffery S | Buy | 2,000 | $24.66 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 323,508 shares shorted. With 11,297,607 shares available for purchase and an average trading volume over the past 10 trading days of 143,520, it would take at least 2.3 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
Over the 12 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $282.3 million against net income of $232.3 million, or 1.22 times. Net income was negative in 5 of the 17 years, and those years are left out of the ratio.
In 2025, net income was -$10.9 million and operating cash flow was $11.2 million, so no ratio is shown for that year.
In 2025, capital expenditures were $6.8 million, 61.0% of operating cash flow of $11.2 million, which leaves an estimated $4.4 million after capex. Across the 16 years with reported capex, it averaged 25.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2009 | 3.7 | 3.1 | 4.0 | 0.84 |
| 2010 | 4.3 | 7.9 | 2.8 | 1.82 |
| 2011 | 8.5 | 10.2 | 1.4 | 1.20 |
| 2012 | 11.8 | 10.5 | 1.5 | 0.90 |
| 2013 | 20.6 | 25.2 | 0.4 | 1.22 |
| 2014 | 38.3 | 40.0 | 1.6 | 1.04 |
| 2015 | 30.8 | 39.9 | 9.2 | 1.30 |
| 2016 | 32.5 | 24.4 | 14.0 | 0.75 |
| 2017 | 31.8 | 40.8 | 9.0 | 1.28 |
| 2018 | 18.7 | 34.9 | 4.7 | 1.87 |
| 2019 | 27.2 | 37.0 | 2.8 | 1.36 |
| 2020 | -24.0 | 13.1 | 1.6 | n/a |
| 2021 | 4.1 | 8.4 | 5.1 | 2.03 |
| 2022 | -14.9 | 4.4 | 7.5 | n/a |
| 2023 | -82.7 | -1.8 | 5.4 | n/a |
| 2024 | -56.4 | 5.4 | 7.7 | n/a |
| 2025 | -10.9 | 11.2 | 6.8 | n/a |
Revenue was $40.1 million in 2009 and $112.8 million in 2025, a compound annual growth rate of 6.7% over 16 years.
Revenue fell 5.9% from 2024 to 2025.
Our estimated free cash flow was $4.7 million in 2025, 4.1% of revenue. In 2009 the estimated margin was negative 2.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 40.1 | -0.9 | -2.2% |
| 2010 | 55.6 | 4.5 | 8.1% |
| 2011 | 64.8 | 7.5 | 11.5% |
| 2012 | 71.4 | 8.1 | 11.4% |
| 2013 | 75.1 | 23.1 | 30.8% |
| 2014 | 105.6 | 38.4 | 36.4% |
| 2015 | 93.0 | 37.1 | 39.9% |
| 2016 | 103.4 | 19.1 | 18.5% |
| 2017 | 113.4 | 34.0 | 30.0% |
| 2018 | 105.6 | 27.2 | 25.8% |
| 2019 | 114.6 | 29.1 | 25.4% |
| 2020 | 130.5 | 6.6 | 5.1% |
| 2021 | 147.8 | 3.8 | 2.5% |
| 2022 | 113.8 | 0.1 | 0.1% |
| 2023 | 120.8 | -6.3 | -5.2% |
| 2024 | 119.9 | -0.1 | -0.1% |
| 2025 | 112.8 | 4.7 | 4.1% |
In 2025, cash and equivalents were $57.5 million against total liabilities of $46.8 million, or 122.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 24.6% of total assets in 2025, compared with 33.9% in 2010, a decrease of 9.3 percentage points.
Stockholders equity was $143.5 million in 2025, compared with $85.2 million in 2010, a rise of 68.4%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 4.2% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 128.9 | 28.2 | 43.7 | 85.2 |
| 2011 | 132.8 | 35.8 | 38.1 | 94.8 |
| 2012 | 142.1 | 44.1 | 33.1 | 108.9 |
| 2013 | 156.0 | 63.3 | 20.4 | 135.6 |
| 2014 | 192.8 | 100.2 | 14.7 | 178.1 |
| 2015 | 235.7 | 110.7 | 24.9 | 210.8 |
| 2016 | 240.2 | 104.3 | 17.5 | 222.8 |
| 2017 | 282.6 | 133.3 | 19.1 | 263.5 |
| 2018 | 279.0 | 89.0 | 15.4 | 263.6 |
| 2019 | 330.7 | 157.5 | 42.3 | 288.4 |
| 2020 | 365.6 | 95.8 | 93.2 | 272.4 |
| 2021 | 347.5 | 94.4 | 60.5 | 287.1 |
| 2022 | 349.1 | 86.3 | 63.6 | 285.6 |
| 2023 | 270.6 | 68.7 | 58.4 | 212.3 |
| 2024 | 202.7 | 55.6 | 48.8 | 154.0 |
| 2025 | 190.3 | 57.5 | 46.8 | 143.5 |
We do not estimate a fair value for Anika Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.
Only 14 of the 17 fiscal years under Anika Therapeutics's current filer show positive free cash flow.
Free cash flow is volatile from year to year, with a variability measure of 100%.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
No dividend yield is recorded for Anika Therapeutics in our data.
Every fiscal year on this page is reported by one SEC filer, CIK 898437.
Each figure on this page comes from that filer.
Advertisement supports free stock analysis content.
Does Anika Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to ANIK: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Share Price of a Company?
What is Cash Return on Invested Capital?
When is the Right Time to Buy a Stock?
How to Make Money with Penny Stocks
Silver Price Today: XAG/USD Spot Price per Ounce, Explained